Arndt Vogel - Researcher Profile | RDL Research Database

Publications

3 shown

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo , Richard S. Finn , Shukui Qin +19 more

2018 The Lancet 5118 citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

2018 The Lancet Oncology 2448 citations

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa , Vaibhav Sahai , Antoine Hollebecque +16 more

Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, ...

2020 The Lancet Oncology 1455 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 9,021
Institution: Medizinische Hochschule Hannover

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-0560-5538

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.